Two randomized phase 3 trials investigating the safety and efficacy of adding pembrolizumab to standard-of-care therapies for multiple myeloma were halted due to poor outcomes in their respective intervention arms.
Retrospective population-based cohort study is used to validate a new risk assessment tool to identify patients receiving immunomodulatory drugs for multiple myeloma who may be at high risk of VTE.
Patients with newly diagnosed malignant lymphoma or multiple myeloma who reported depressive symptoms prior to the start of chemotherapy had poorer survival, researchers found.
In this retrospective study, researchers investigated whether assessing left ventricular diastolic function in patients receiving carfilzomib for relapsed or refractory multiple myeloma improved risk of cardiovascular adverse events.
